Initial testing of aplidin by the pediatric pre‐clinical testing program
Year: 2009
Type: article
Abstract: Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 microM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days x 3-schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43%) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions.
Source: Pediatric Blood & Cancer
DOI: 10.1002/pbc.21976
Institutions: St. Jude Children's Research Hospital, Children's Hospital at Montefiore, Alfred I. duPont Hospital for Children, Children's Cancer Institute Australia, Duke Medical Center, Texas Tech University, Texas Tech University Health Sciences Center, Children's Hospital of Philadelphia, University of Pennsylvania, National Institutes of Health, National Cancer Institute
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2040661351